EV/EBITDA
Updated 102h ago
Sector Performance
69th percentileCME
18.8x
Sector Median
13.7x
Sector Avg
18.4x
Deep Analysis
CME’s current EV/EBITDA of 18.8x means the company’s total enterprise value is 18.8 times its earnings before interest, taxes, depreciation, and amortization — a measure used to assess whether a stock is cheap or expensive relative to its operating cash flow.
This multiple sits well above the sector median of 13.6x, placing the company in the 70th percentile among its peers, indicating a premium valuation. The metric has been stable over the last eight quarters, with no year-over-year change data available, and a quarter-over-quarter increase of +4.3%. The combination of a high EV/EBITDA level and a stable, slightly rising trend suggests limited upside potential from valuation expansion, pointing to a balanced risk-opportunity profile rather than a clear bargain or bubble. This metric supports the overall NEUTRAL verdict because the premium multiple is not justified by a meaningful deterioration, yet it offers no compelling margin of safety for aggressive entry.
Frequently Asked Questions
What does the EV/EBITDA tell investors about CME?
A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.
How is the EV/EBITDA calculated?
EV/EBITDA is calculated as: Enterprise Value / EBITDA.
Who are CME's closest peers by EV/EBITDA?
The closest peers by EV/EBITDA include: LSPD (-24.2x), BRZE (-24.5x), EVGO (-25.7x), NIO (-36.8x), SNAP (-38.8x).
The Formula
Enterprise Value / EBITDA
Why It Matters
A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.
Master CME's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full CME research report →CME
18.8x
Sector Median
13.7x
Sector Avg
18.4x
How CME's EV/EBITDA compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.